ANGO — Stock Film
STOCK FILMSCENE 1/11ANGO · $10.60
Stock Expert AI presents
ANGO
AngioDynamics, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
AngioDynamics, Inc. A quick introduction.

On the stock market since 2004, it operates in the world of health and science. It has 748 employees. Now — the numbers.

on the stock market since 2004
748 employees
$436.9M market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $1.1.

The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.

WHERE DOES THE MONEY COME FROM?
65%Med Device
Med Device 65%Med Tech 35%
65% of all revenue comes from a single line: Med Device.

That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.

In the vault right now:
$0
DEBT: $0
At this pace, that money lasts about 1.5 years.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
71
strong

Clearly above the class average — a step short of the very top.

FINANCIAL STRENGTH
52
average

A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.

VALUATION
63
average

The price isn’t cheap next to earnings — that’s why this grade sits in the middle.

GROWTH
52
average

There is growth, but not at top-of-the-class tempo.

PRICE MOMENTUM
80
very strong

The stock has been running stronger than the market lately.

No real weak spot in any of the five subjects — a balanced report card.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 3 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Fat profit per sale, but shrinking8/10
Few are betting against it10/10
WEAK SPOTS
Growth has stalled2/10
WORTH WATCHING

Revenue Growth: Sales are growing slowly.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 66% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/3
Sales are holding up

The company sells $320.2M a year; the problem isn’t sales — it’s costs running above that number.

2
THE BRIGHT SIDE · 2/3
Delivers on expectations

It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.

3
THE BRIGHT SIDE · 3/3
Executives are buying their own stock

Over the last 12 months, company executives reported 28 buys and 17 sells. Management buying with its own money is usually read as a good sign.

1
THE RISKS · 1/2
Running at a loss

A loss of $36.7M against $320.2M in annual sales.

2
THE RISKS · 2/2
The cash has a countdown

At the current pace of spending, the cash lasts about 1.5 years. After that, the company needs to find new money.

FINALE · THE GRADE
D
0 / 100 · MoonshotScore

On our five-subject report card, ANGO sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: ANGO is a small company that closed last year at a loss. The road back to profit runs through spending discipline.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Jul 21, 2026 · stockexpertai.com · Stock Film